Orphan Drugs Market Size, Share, and Trends 2025 to 2034

The global orphan drugs market size is calculated at USD 216.55 billion in 2025 and is predicted to surpass around USD 610.24 billion by 2034, representing a healthy CAGR of 12.20% between 2025 and 2034. The North America orphan drugs market size is calculated at USD 84.92 billion in 2024 and is expected to grow at a fastest CAGR of 12.32% during the forecast year. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

Last Updated : May 2025  |  Report Code : 2238  |  Category : Healthcare  |  Format : PDF / PPT / Excel

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Orphan Drugs Market 

5.1. COVID-19 Landscape: Orphan Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Orphan Drugs Market, By Drug Type

8.1. Orphan Drugs Market, by Drug Type

8.1.1 Biologicals

8.1.1.1. Market Revenue and Forecast

8.1.2. Non-Biologicals

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Orphan Drugs Market, By Therapy

9.1. Orphan Drugs Market, by Therapy

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast

9.1.2. Haematology

9.1.2.1. Market Revenue and Forecast

9.1.3. Neurology

9.1.3.1. Market Revenue and Forecast

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast

9.1.5. Metabolic Disorders

9.1.5.1. Market Revenue and Forecast

9.1.6. Endocrinology

9.1.6.1. Market Revenue and Forecast

9.1.7. Immunology

9.1.7.1. Market Revenue and Forecast

9.1.8. Others

9.1.8.1. Market Revenue and Forecast

Chapter 10. Global Orphan Drugs Market, By Distribution Channel 

10.1. Orphan Drugs Market, by Distribution Channel

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast

10.1.4. Others

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Orphan Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Type

11.1.2. Market Revenue and Forecast, by Therapy

11.1.3. Market Revenue and Forecast, by Distribution Channel

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Type

11.1.4.2. Market Revenue and Forecast, by Therapy

11.1.4.3. Market Revenue and Forecast, by Distribution Channel

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Type

11.1.5.2. Market Revenue and Forecast, by Therapy

11.1.5.3. Market Revenue and Forecast, by Distribution Channel

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Type

11.2.2. Market Revenue and Forecast, by Therapy

11.2.3. Market Revenue and Forecast, by Distribution Channel

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Type

11.2.4.2. Market Revenue and Forecast, by Therapy

11.2.4.3. Market Revenue and Forecast, by Distribution Channel

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Type

11.2.5.2. Market Revenue and Forecast, by Therapy

11.2.5.3. Market Revenue and Forecast, by Distribution Channel

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Type

11.2.6.2. Market Revenue and Forecast, by Therapy

11.2.6.3. Market Revenue and Forecast, by Distribution Channel

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Type

11.2.7.2. Market Revenue and Forecast, by Therapy

11.2.7.3. Market Revenue and Forecast, by Distribution Channel

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Type

11.3.2. Market Revenue and Forecast, by Therapy

11.3.3. Market Revenue and Forecast, by Distribution Channel

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Type

11.3.4.2. Market Revenue and Forecast, by Therapy

11.3.4.3. Market Revenue and Forecast, by Distribution Channel

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Type

11.3.5.2. Market Revenue and Forecast, by Therapy

11.3.5.3. Market Revenue and Forecast, by Distribution Channel

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Type

11.3.6.2. Market Revenue and Forecast, by Therapy

11.3.6.3. Market Revenue and Forecast, by Distribution Channel

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Type

11.3.7.2. Market Revenue and Forecast, by Therapy

11.3.7.3. Market Revenue and Forecast, by Distribution Channel

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Type

11.4.2. Market Revenue and Forecast, by Therapy

11.4.3. Market Revenue and Forecast, by Distribution Channel

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Type

11.4.4.2. Market Revenue and Forecast, by Therapy

11.4.4.3. Market Revenue and Forecast, by Distribution Channel

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Type

11.4.5.2. Market Revenue and Forecast, by Therapy

11.4.5.3. Market Revenue and Forecast, by Distribution Channel

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Type

11.4.6.2. Market Revenue and Forecast, by Therapy

11.4.6.3. Market Revenue and Forecast, by Distribution Channel

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Type

11.4.7.2. Market Revenue and Forecast, by Therapy

11.4.7.3. Market Revenue and Forecast, by Distribution Channel

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Type

11.5.2. Market Revenue and Forecast, by Therapy

11.5.3. Market Revenue and Forecast, by Distribution Channel

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Type

11.5.4.2. Market Revenue and Forecast, by Therapy

11.5.4.3. Market Revenue and Forecast, by Distribution Channel

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Type

11.5.5.2. Market Revenue and Forecast, by Therapy

11.5.5.3. Market Revenue and Forecast, by Distribution Channel

Chapter 12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Celgene Corporation

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Merk & Co., Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Novartis AG

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Sanofi

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Takeda Pharmaceutical Company Limited

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Alexion Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Amgen Inc

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

13.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global orphan drugs market size was valued at USD 193.01 billion in 2024 and it is projected to hit around USD 610.24 billion by 2034.

The global orphan drugs market is poised to grow at a CAGR of 12.20% from 2025 to 2034.

The major players operating in the orphan drugs market are F. Hoffmann-La Roche Ltd, Celgene Corporation, Merk & Co., Inc., Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, AstraZeneca, Alexion Pharmaceuticals Inc., Eli Lilly and Company, and Amgen Inc.

The implementation of effective government policies supporting the development and adoption of innovative orphan drug therapies these are the driving factors of the orphan drugs market.

North America region will lead the global orphan drugs market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client